Effects of ACEI on Bone Turnover

The University of Texas System (UT)

Status: Completed

Conditions: Bone Turnover Status in Hypertensive Patients

Study type: Observational

Funder types: Other; Other U.S. Federal agency

Identifiers

NCT02377440

HSC-MS-13-0634

Details and patient eligibility

About

The investigators hypothesize that older persons (≥45 years) treated with ACEI for HTN control will have: i) improved status of bone turnover (decreased P1NP and CTX), and ii) decreased levels of RANKL and RANKL/OPG, compared to those not treated with ACEI and not using RAS-related medications

Enrollment: 32 patients

Sex: All

Ages: 45+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• at least 45 years of age
• a diagnosis of (either new or uncontrolled) HTN who will need a new medication for HTN control
• able to consent (no medial issues impairing judgment for consenting based on clinical providers' judgment).

Exclusion criteria

• younger than 45 years of age
• a diagnosis of metabolic bone disease
• a diagnosis of osteoporosis or use of medication to treat osteoporosis
• a diagnosis of diabetes mellitus, or renal insufficiency, or cancer
• history of allergy to ACEI or ARB, 6) history of use of ACEI or ARB.